TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy

Carl Maximilian Thielmann, Johanna Matull, Anne Zaremba, Rajmohan Murali, Eleftheria Chorti, Georg Lodde, Philipp Jansen, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Michael Weichenthal, Julia Kretz, Inga Möller, Antje Sucker, Annette Paschen, Elisabeth Livingstone, Lisa Zimmer, Eva Hadaschik, Selma Ugurel, Dirk Schadendorf, Klaus Griewank